|
1000
|
Abstract/Summary
|
-
<jats:p><jats:bold>Background:</jats:bold> Severe thrombocytopenia is a common complication of extracorporeal membrane oxygenation (ECMO). Oseltamivir can be used to treat infection-associated thrombocytopenia.</jats:p><jats:p><jats:bold>Objective:</jats:bold> To evaluate the effect of oseltamivir on attenuating severe thrombocytopenia during ECMO.</jats:p><jats:p><jats:bold>Methods:</jats:bold> This was a single-center real-world study in critically ill patients supported with venous-arterial extracorporeal membrane oxygenation (VA-ECMO). Patients suspected or confirmed with influenza received oseltamivir according to the Chinese guidelines. Thrombocytopenia and survival were compared between the oseltamivir-treated and untreated group. The factors associated with survival were analyzed by multivariable Cox analysis.</jats:p><jats:p><jats:bold>Results:</jats:bold> A total of 82 patients were included. All patients developed thrombocytopenia after initiating VA-ECMO. Twenty-three patients received oseltamivir (O<jats:sup>+</jats:sup> group), and 59 did not use oseltamivir (O<jats:sup>−</jats:sup> group). During the first 8 days after VA-ECMO initiation, the platelet count in the O<jats:sup>+</jats:sup> group was higher than that in the O<jats:sup>−</jats:sup> group (all <jats:italic>P</jats:italic> &lt; 0.05). The patients in the O<jats:sup>+</jats:sup> group had a higher median nadir platelet count (77,000/μl, 6,000–169,000/μl) compared with the O<jats:sup>−</jats:sup> group (49,000/μl, 2,000–168,000/μl; <jats:italic>P</jats:italic> = 0.04). A nadir platelet count of &lt;50,000/μl was seen in 26% of the patients in the O<jats:sup>+</jats:sup> group, compared with 53% in the O<jats:sup>−</jats:sup> group (<jats:italic>P</jats:italic> = 0.031). No significant difference in survival from cardiac failure was seen between the O<jats:sup>+</jats:sup> and O<jats:sup>−</jats:sup> group (48 vs. 56%, <jats:italic>P</jats:italic> = 0.508). The Sequential Organ Failure Assessment (SOFA) score on initiation of VA-ECMO were independently associated with survival (OR = 1.12, 95% confidence interval (95% CI): 1.02–1.22, <jats:italic>P</jats:italic> = 0.015).</jats:p><jats:p><jats:bold>Conclusions:</jats:bold> Oseltamivir could ameliorate VA-ECMO-related thrombocytopenia. These findings suggested the prophylactic potential of oseltamivir on severe thrombocytopenia associated with the initiation of VA-ECMO.</jats:p>
|
|
1000
|
Hinweis
|
-
DeepGreen-ID: 3509835f4ed64dd3ab16b49028ac5884 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
|
